1441 North 34th Street
Integrated Diagnostics Inc.
Integrated Diagnostics Inc. aims to deliver on the long-heralded promise of personalized medicine with simple blood tests capable of diagnosing disease and spotlighting problems even before a patient notices signs of clinical disease. These new tests might also help physicians determine which type of drug is best suited for a particular patient, and monitor patients' response to treatment.
More from Archive
More from Medtech Insight
• By
The Oncodetect test is tumor-informed, tracking up to 200 circulating tumor DNA (ctDNA) variants. It delivers simple “detected” or “not detected” results alongside quantitative data to guide adjuvant therapy decisions, monitor treatment response, and detects up to 200 ctDNA variants identifying signs of colorectal cancer recurrence up to two years earlier than imaging.
• By
Diabetes company Insulet announced that former longtime J&J executive Ashley McEvoy will succeed Jim Hollingshead as president and CEO effective today. Analysts applauded the appointment, noting McEvoy’s strong background in medtech and diabetes.
• By
Medtech Insight sat down with Jared Bunch, chair of AF Center of Excellence Task Force, at HRS 2025 to discuss the newly HRS released framework for Afib Center of Excellence and get his perspective on the role industry could play to help clinicians improve patient outcomes.